Increased natriuretic peptides not associated with heart failure

Increased natriuretic peptides not associated with heart failure

Natriuretic peptides (NPs) are key diagnostic and prognostic biomarkers for patients with heart failure (HF). The main mechanism for increasing serum NP levels, which is characteristic of heart failure, is secretion in response to myocardial wall distention. At the same time, according to Russian an...

Full description

Bibliographic Details
Main Authors:	A. M. Chaulin, D. V. Duplyakov
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2021-01-01
Series:	Российский кардиологический журнал
Subjects:	natriuretic peptides heart failure exercise renal failure atrial fibrillation sacubitril/valsartan false positive causes of elevation
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/4140

Similar Items

Renin profiling predicts neurohormonal response to sacubitril/valsartan
by: Giuseppe Vergaro, et al.
Published: (2021-02-01)

Potential and Limitations of Atrial Natriuretic Peptide as Biomarker in Pediatric Heart Failure—A Comparative Review
by: Tanja Gangnus, et al.
Published: (2019-01-01)

Effect of sacubitril/valsartan on inflammation and oxidative stress in doxorubicin-induced heart failure model in rabbits
by: Yu Chun, et al.
Published: (2021-09-01)

Atrial Natriuretic Peptides as a Bridge between Atrial Fibrillation, Heart Failure, and Amyloidosis of the Atria
by: Farzad Rahbar Kouibaran, et al.
Published: (2023-03-01)

Combined drug sacubitril/valsartan -a new era of treatment of chronic heart failure
by: V. S. Nikiforov
Published: (2020-10-01)

First signs of reverse cardiac remodeling following one-month, low dose add-on sacubitril-valsartan therapy in patients with advanced systolic heart failure
by: Wioletta Sacharczuk, et al.
Published: (2022-03-01)

Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure
by: Reza Mohebi, et al.
Published: (2023-04-01)

Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
by: David Carballo, et al.
Published: (2020-06-01)

Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
by: Ying‐Hsiang Lee, et al.
Published: (2021-04-01)

Natriuretic peptides and their usefulness in clinical practise
by: Aleksandra Skałecka, et al.
Published: (2020-09-01)

Supramolecular complex sacubitril/valsartan - the first representative of a new class of drugs for the treatment of chronic heart failure
by: T. V. Ashcheulova, et al.
Published: (2019-12-01)

Plasma B-type natriuretic peptide concentration for diagnosis of acute heart failure with renal insufficiency
by: Naila Atik Khan, et al.
Published: (2016-07-01)

Impact of Sacubitril/Valsartan on Circulating microRNA in Patients with Heart Failure
by: Maura Brioschi, et al.
Published: (2023-03-01)

Sacubitril/Valsartan for Heart Failure: Exciting Times but Are Doctors Informed and Ready?
by: Prithwish Banerjee
Published: (2017-01-01)

Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy
by: Vanesa Gregorietti, et al.
Published: (2020-11-01)

Sacubitril/valsartan in patients listed for heart transplantation: effect on physical frailty
by: Francesco Cacciatore, et al.
Published: (2020-04-01)

Efficacy and safety of sacubitril‐valsartan in heart failure: a meta‐analysis of randomized controlled trials
by: Hongzhou Zhang, et al.
Published: (2020-12-01)

Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM‐HF
by: Su E. Yeoh, et al.
Published: (2020-12-01)

Physiology and clinical significance of natriuretic hormones
by: Sandeep Chopra, et al.
Published: (2013-01-01)

Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials
by: Magnus O. Wijkman, et al.
Published: (2022-06-01)

Sacubitril/valsartan for heart failure in patients with complex adult congenital heart disease – Experience from a tertiary centre in Singapore
by: Limin Yan, et al.
Published: (2021-12-01)

Effects and clinical outcomes of early initiation of sacubitril/valsartan in patients with chronic heart failure with a low ejection fraction
by: Z. D. Kobalava, et al.
Published: (2020-12-01)

Natriuretic peptides: Diagnostic and therapeutic use
by: Kaushik Pandit, et al.
Published: (2011-01-01)

The Effects of Exercise on Natriuretic Peptides in Individuals without Heart Failure
by: Hidetaka Hamasaki
Published: (2016-05-01)

Effects and clinical implications of sacubitril/valsartan on left ventricular reverse remodeling in patients affected by chronic heart failure: A 24-month follow-up
by: Carla Paolini, et al.
Published: (2021-08-01)

The influence of comorbidities on achieving an N‐terminal pro‐b‐type natriuretic peptide target: a secondary analysis of the GUIDE‐IT trial
by: Justin A. Ezekowitz, et al.
Published: (2022-02-01)

INTEGRATION OF BIOMARKERS INTO THE PRACTICE OF TREATING PATIENTS WITH HEART FAILURE: THE ROLE OF DETERMINING THE BLOOD LEVEL OF NATRIURETIC PEPTIDES
by: S. R. Gilyarevskiy, et al.
Published: (2017-12-01)

B-type natriuretic peptide (BNP): can it improve our management of patients with congestive heart failure?
by: Swiss Medical Weekly
Published: (2002-11-01)

How to Use Natriuretic Peptides in Patients with Heart Failure with Non-Reduced Ejection Fraction?
by: Ahmet Çelik, et al.
Published: (2023-05-01)

B-type natriuretic peptide for diagnosis and treatment of congestive heart failure
by: GM Kuster, et al.
Published: (2002-11-01)

Usefulness of brain natriuretic peptide for predicting left atrial appendage thrombus in patients with unanticoagulated nonvalvular persistent atrial fibrillation
by: Yusuke Ochiumi, MD, et al.
Published: (2015-10-01)

The protocol and rationale for the efficacy aNd ToleRability of sacUbitril-valSarTan in adult congenital heart disease patients with heart failure (ENTRUST ACHD HF) registry
by: V Appadurai, et al.
Published: (2021-05-01)

Clinical Utility of Baseline Brain Natriuretic Peptide Levels on Health Status Outcomes after Catheter Ablation for Atrial Fibrillation in Individuals without Heart Failure
by: Shin Kashimura, et al.
Published: (2024-01-01)

Neuroendocrine hormone status and diuretic response to atrial natriuretic peptide in patients with acute heart failure
by: Shingo Matsumoto, et al.
Published: (2022-12-01)

Brain natriuretic peptide, structural and functional cardiac remodeling in chronic heart failure with overweight and obesity
by: V. D. Syvolap, et al.
Published: (2014-06-01)

Effectiveness of sacubitril–valsartan in cancer patients with heart failure
by: Ana Martín‐Garcia, et al.
Published: (2020-04-01)

Reverse Remodeling and Functional Improvement of Left Ventricle in Patients with Chronic Heart Failure Treated with Sacubitril/Valsartan: Comparison between Non-Ischemic and Ischemic Etiology
by: Roberto Cemin, et al.
Published: (2023-01-01)

The Use of Brain Natriuretic Peptide in the Evaluation of Heart Failure in Geriatric Patients
by: Mihai Marinescu, et al.
Published: (2023-04-01)

The Efficacy and Safety of Sacubitril/Valsartan Compared to Valsartan in Patients with Heart Failure and Mildly Reduced and Preserved Ejection Fractions: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Sharath Kommu, et al.
Published: (2024-03-01)

Earlier is Better. New Options for Acute Heart Failure: When, Who, How Much?
by: Nechita Alexandru Cristian
Published: (2022-12-01)